TARDBP and frontotemporal dementia: Rather than using disease models of TDP-43 such as transient over-expression or recombinant proteins for antibody development, recent data suggests that it might be necessary to specifically isolate the pathological forms of TDP-43 from ALS and FTD postmortem tissue and biofluids.